26 Years Since its Approval, Dr. Heidi Overton’s Nomination Leaves Mifepristone in Limbo

Last week, the US Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing for President Donald Trump’s nominee to lead the Food and Drug Administration (FDA), Dr. Heidi Overton.

During the hearing, Dr. Overton followed suit with many of Trump’s previous nominees for federal agencies—avoiding questions, obscuring her true intentions, and feigning ignorance of her own public record on a range of topics.

Her nomination comes at a fraught moment for the agency. The FDA is facing heavy criticism following a Cyclospora outbreak that sickened many and rattled the public. The prior commissioner abruptly resigned after only 13 months in the role. The agency has also wrestled with political pressure on everything from reproductive health to vaccinations to flavored e-cigarettes, imperiling its historic scientific neutrality and risking a descent into partisan miasma.

Dr. Overton remains dangerously out of step with the general public, medicine, and science on the subject of medication abortion with mifepristone and her record explicitly showcases that she will do everything in her power to ban medication abortion.

The FDA works best when publicly unnoticed, operating smoothly and uncontroversially in the background of our country, keeping us safe. It is vital to our economy as well as our health. Take, for example, my home state of Ohio. Healthcare is our largest employment sector, and nearly half of our land is farmland. As a maternal fetal medicine physician, the scope of my work is providing the best care to my patients and advising on the available options to receive comprehensive medical care.

Therefore, we need an FDA leader steeped in objective, scientific neutrality rather than the culture wars Americans are so tired of — and Dr. Overton is a far cry from what is needed in this moment.

This week marks 26 years since the FDA initially approved mifepristone as safe and effective. Since the Dobbs decision, mifepristone has emerged as a linchpin in the preservation of access to abortion care for millions of patients. It also rests atop an enormous bedrock of research and clinical trials expounding its safety and efficacy.

As of December 2025, medication abortion has accounted for 65% of all US abortions, and one in four clinician-provided abortions were delivered through telehealth. Mifepristone specifically is used to support patients with their reproductive care and is even recommended by the American College of Obstetricians and Gynecologists for miscarriage management.

The American Medical Association has stated that serious adverse events occur in fewer than one-third of one percent of patients who take mifepristone, and continuing a pregnancy carries roughly 14 times the risk of death than abortion related complications. Reimposing in-person requirements, the AMA warns, would eliminate access for rural, low-income, and underserved patients and limit the quality of care that doctors are able to provide. In February 2026, ACOG led a coalition of 15 medical organizations in defending mifepristone's safety record in court.

And yet, Dr. Overton remains dangerously out of step with the general public, medicine, and science on the subject of medication abortion with mifepristone and her record explicitly showcases that she will do everything in her power to ban medication abortion.

She celebrated the overturning of Roe v. Wade as “a huge victory for life,” dismissed federal legislation protecting abortion rights as “radicalism,” and has promoted misinformation about the safety of medication abortion that contradicts more than two decades of evidence. As a member of the America First Policy Institute, Overton authored position papers advocating draconian federal regulation of medication abortion. Such measures would dangerously cripple access to safe abortion.

Her nomination to this role is a threat to women’s health, the credibility of the FDA, and the wellbeing of every American. That’s why I joined over 160+ patients, physicians, and advocates from across the country in signing a letter to Senators to reject her nomination.

Beyond politics, it has been noted that Dr. Overton lacks the administrative experience necessary to manage an organization as large as the FDA, with thousands of employees. If confirmed, she would report to an HHS secretary who also lacked significant administrative experience. When RFK Jr. faced nomination, much of the focus was on his lack of training in science, medicine, or healthcare. Less discussed was his lack of management experience, the consequences of which have been evident in the organizational disarray at HHS.

Dr. Overton has laudable academic credentials, including a PhD from Johns Hopkins. But a prestigious degree and impressive publications alone are not enough to lead one of the country’s most consequential healthcare agencies. They are the table stakes, not the winning hand.

You have to have experience running a large organization to be charged with leading another large organization. Given the respective stakes at the FDA, we should not be rolling those dice.

A physician-leader who can do everything is a truly amazing person: someone who treats patients as a doctor, educates as a teacher, investigates as a scientist, and manages thousands of employees with administrative ease. Such people are rare, but they exist. We know who they are, and these are the people who should be considered for such a critical role at the FDA — not Dr. Overton

If confirmed, Dr. Overton will join the growing list of notably unqualified candidates this administration has nominated at the expense of the American people, and we must continue to speak up against these affronts on our democracy.